SAGE's earnings and revenues miss estimates in the first quarter of 2025. The company focuses on the commercialization of its depression drug Zurzuvae.

Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the first quarter ended March 31, 2025.

Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer ...

--(BUSINESS WIRE)-- Sage Therapeutics, Inc. (SAGE), today reported ... Collaboration revenue represents 50% of the net revenue recorded when Biogen ships ZURZUVAE to the distributors.

Achieved $13.8 million in ZURZUVAE® (zuranolone) collaboration revenue in the first quarter of 2025 (50% of the net revenues recorded by Biogen ... remains ongoing Sage Therapeutics, Inc ...

Sage Therapeutics, Inc. SAGE reported a loss of $1.01 per share for the first quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 99 cents. The company had reported a loss of $1. ...

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...